UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
March 27, 2024 08:34 ET
|
TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223...
Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
March 27, 2024 08:00 ET
|
TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for...
TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer
July 06, 2023 09:19 ET
|
TellBio, Inc
-- Prostate Circulating Tumor Cells Isolated with TellDx Technology Demonstrates Epigenetic Changes that Silence Immune Surveillance Genes and Spare Proliferation-Associated Genes -- -- Breast Cancer...
Circulating Tumor Cells Isolated with Unique TellDx Technology May Help Predict Response to Therapy in Patients with Progressive Metastatic Breast Cancer
May 22, 2023 08:00 ET
|
TellBio, Inc
-- CTCs isolated with TellDx leveraged to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a select cohort of patients with metastatic breast...
Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma
March 16, 2023 08:00 ET
|
TellBio, Inc
--Interrogation of circulating tumor cells (CTCs) shows downregulation of KEAP1 gene promotes resistance to immune checkpoint blockade in melanoma-- --Study provides valuable insights into the...
Reduction in Circulating Tumor Cells (CTC), Enriched by TellBio Platform, with Novel Dual-Cadherin Antibody (23C6) Results in Significant Metastasis Suppression
October 24, 2022 08:00 ET
|
TellBio, Inc
-- TellDx CTC System can be leveraged to monitor efficacy of novel therapeutic agents— --Targeting multiple cadherins with 23C6 can ameliorate cancer metastasis-- -- TellBio has exclusive...
Circulating Tumor Cell (CTC) Isolation with TellDx Technology Could Inform Personalized Drug Treatment in Prostate Cancer
January 20, 2022 16:42 ET
|
TellBio, Inc
-- Single-cell proteomics can elucidate kinase activity in prostate cancer models -- -- Kinase activity in bone metastases and epithelial circulating tumor cells is elevated -- BEVERLY, Mass., Jan. ...
TellBio’s Scientific Founders Publish Very High Concordance between CTCs and ctDNA from Liquid Biopsies in Patients with Breast Cancer
July 15, 2021 08:00 ET
|
TellBio, Inc
--Rare parallel analyses of directly matched CTCs, utilizing TellBio’s TellDx platform, and ctDNA samples showing 95% concordance published in Breast Cancer Research and Treatment-- --Isolation of...
TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer
May 10, 2021 07:00 ET
|
TellBio, Inc
--Closes $5 million Series A financing-- --Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations-- ...